程序性死亡受体1及程序性死亡受体配体1抑制剂在小细胞肺癌治疗中的进展

Progress of PD-1/PD-L1 inhibitors in the treatment of small-cell lung cancer

小细胞肺癌(SCLC)约占肺癌的15%,是一种神经内分泌肿瘤,生长迅速、极具侵袭性,容易早期发生远处转移。尽管SCLC对一线化疗敏感,但容易短时间内复发。在过去的5年间,免疫治疗在SCLC中取得了一定的成果,特别是在程序性死亡受体1和程序性死亡受体配体1方面,SCLC治疗模式已经发生改变。文章对免疫检查点抑制剂在SCLC中的探索研究做一综述,以期为广大临床工作者提供参考。

Small cell lung cancer(SCLC)is a neuroendocrine tumor,which accounts for about 15%of all lung cancers.SCLC is characterized by rapid growth and tendency to widespread metastasis at the initial stage.Although high response rates to first-line chemotherapy are observed,most patients relapse less than few months.In the past 5 years,some clinical trials found that the immune checkpoint inhibitors(ICIs)were effective in SCLC,especially programmed cell death 1/ligand 1(PD-1/L1).Given this situation,the treatment patterns of SCLC have changed.This article briefly reviews the researches and studies of ICIs in the treatment of SCLC to provide reference to the clinicians.